SCOPUS 정보 검색 플랫폼

Volumn 61, Issue SUPPL. 2, 2001, Pages 14-21

Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials

(1) Baselga, José a

a HOSPITAL UNIVERSITARI VALL D HEBRON (Spain)

Author keywords

FISH; HER2 positive; Herceptin ; IHC 3+; Metastatic breast cancer; Pivotal trial; Survival benefit

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; RECEPTOR SUBTYPE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; MONOCLONAL ANTIBODY; TUMOR PROTEIN;

BREAST CARCINOMA; CANCER SURVIVAL; CHEMOTHERAPY; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERANCE; DRUG USE; FEVER; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; RESPONSE TIME; TREATMENT OUTCOME; ADULT; BREAST TUMOR; CHEMISTRY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; METASTASIS; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; REVIEW; SAFETY; SINGLE BLIND PROCEDURE; SURVIVAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTICENTER STUDIES; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PACLITAXEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SAFETY; SINGLE-BLIND METHOD; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034760143 PISSN: 00302414 EISSN: None Source Type: Journal
DOI: 10.1159/000055397 Document Type: Conference Paper

Times cited : (165)

References (36)

1
- 0032127350
- Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu-overexpressing human breast cancer xenografts
- (1998) Cancer Res , vol.58 , pp. 2825-2831
- Baselga, J.¹ Norton, L.² Albanell, J.³ Kim, Y.-M.⁴ Mendelsohn⁵

2
- 0029991439
- HER2 monoclonal antibody in patients with HER/neu-overexpressing metastatic breast cancer
- (1996) J Clin Oncol , vol.14 , pp. 737-744
- Baselga, J.¹ Tripathy, D.² Mendelsohn, J.³ Baughman, S.⁴ Benz, C.C.⁵ Dantis, L.⁶ Sklarin, N.T.⁷ Seidman, A.D.⁸ Hudis, C.A.⁹ Moore, J.¹⁰ Rosen, P.P.¹¹ Twaddell, T.¹² Henderson, I.C.¹³ Norton, L.¹⁴

3
- 0000492316
- Health-related Quality of Life (HRQL) in women with HER2-overexpressing, metastatic breast cancer (MBC) in a phase III study of Herceptin® plus chemotherapy versus chemotherapy alone
- (1999) Eur J Cancer , vol.35
- Baselga, J.¹ Kerrigan, M.² Burchmore, M.³ Ash, M.⁴

4
- 0033093978
- First MAb approved for the treatment of metastatic breast cancer
- (1999) J Am Pharm Assoc , vol.39 , pp. 236-238
- Brenner, T.L.¹ Adams, V.R.²

5
- 0032920927
- Quality of life in women with recurrent breast cancer
- (1999) Breast Cancer Research and Treatment , vol.54 , pp. 47-57
- Bull, A.A.¹ Meyerowitz, B.E.² Hart, S.³ Mosconi, P.⁴ Apolone, G.⁵ Liberati, A.⁶

6
- 0000232941
- Herceptin (H) and Navelbine (V) for HER2-positive metastatic breast cancer: A phase II study
- (2000) Proc ASCO , vol.19
- Burstein, H.J.¹ Kuter, I.² Richardson, P.G.³ Campos, S.M.⁴ Matulonis, U.A.⁵ Harris, L.⁶ Garber, J.E.⁷ Younger, J.⁸ Bunnell, C.A.⁹ Shulman, L.N.¹⁰ Winer, E.P.¹¹

7
- 0026610881
- HER2 antibody for human cancer therapy
- (1992) Proc Natl Acad Sci USA , vol.89 , pp. 4285-4289
- Carter, P.¹ Presta, L.² Gorman, C.M.³ Ridgway, J.B.⁴ Henner, D.⁵ Wong, W.L.⁶ Rowland, A.M.⁷ Kotts, C.⁸ Carver, M.E.⁹ Shepard, H.M.¹⁰

8
- 0032850677
- Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
- (1999) J Clin Oncol , vol.17 , pp. 2639-2648
- Cobleigh, M.A.¹ Vogel, C.L.² Tripathy, D.³ Robert, N.J.⁴ Scholl, S.⁵ Fehrenbacher, L.⁶ Wolter, J.M.⁷ Paton, V.⁸ Shak, S.⁹ Lieberman, G.¹⁰ Slamon, D.J.¹¹

9
- 0034755872
- Retrospective analysis of the safety of Herceptin® immunotherapy in metastatic breast cancer
- (2001) Oncology , vol.61 , Issue.SUPPL. 2 , pp. 58-66
- Cook-Bruns, N.¹

10
- 0022399581
- Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
- (1985) Science , vol.230 , pp. 1132-1139
- Coussens, L.¹ Yang-Feng, T.L.² Liao, Y.-C.³ Chen, E.⁴ Gray, A.⁵ McGrath, J.⁶ Seeburg, P.H.⁷ Libermann, T.A.⁸ Schlessinger, J.⁹ Francke, U.¹⁰

11
- 0023663896
- Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells
- (1987) Cell , vol.51 , pp. 1063-1070
- Di Fiore, P.P.¹ Pierce, J.H.² Fleming, T.P.³ Hazan, R.⁴ Ullrich, A.⁵ King, C.R.⁶ Schlessinger, J.⁷ Aaronson, S.A.⁸

12
- 0023196582
- erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
- (1987) Science , vol.237 , pp. 178-182
- Di Fiore, P.P.¹ Pierce, J.H.² Kraus, M.H.³ Segatto, O.⁴ King, C.R.⁵ Aaronson, S.A.⁶

13
- 0026472124
- Expression of the neu protooncogene in the mammary epithelium of transgenic mice includes metastatic disease
- (1992) Proc Natl Acad Sci USA , vol.89 , pp. 10578-10582
- Guy, C.T.¹ Webster, M.A.² Schaller, M.³ Parsons, T.J.⁴ Cardiff, R.D.⁵ Muller, W.J.⁶

14
- 0025986825
- A monoclonal antibody against the C-erbB-2 protein enhances the cytotoxicity of cis-diamminedi-chloroplatinum against human breast and ovarian tumor cell lines
- (1991) Cancer Res , vol.51 , pp. 4575-4580
- Hancock, M.C.¹ Langton, B.C.² Chan, T.³ Toy, P.⁴ Monahan, J.J.⁵ Mischak, R.P.⁶ Shawver, L.K.⁷

15
- 0034755640
- Testing for HER2 status
- (2001) Oncology , vol.61 , Issue.SUPPL. 2 , pp. 22-30
- Hanna, W.¹

16
- 0024478054
- p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
- (1989) Mol Cell Biol , vol.9 , pp. 1165-1172
- Hudziak, R.M.¹ Lewis, G.D.² Winget, M.³ Fendley, B.M.⁴ Shepard, H.M.⁵ Ullrich, A.⁶

17
- 0023430930
- HER2 causes transformation and tumorigenesis of NIH 3T3 cells
- (1987) Proc Natl Acad Sci USA , vol.84 , pp. 7159-7163
- Hudziak, R.M.¹ Schlessinger, J.² Ullrich, A.³

18
- 0028670125
- The biology oferbB-2/neu/HER-2 and its role in cancer
- (1994) Biochim Biophys Acta Rev Cancer , vol.1198 , pp. 165-184
- Hynes, N.E.¹ Stern, D.F.²

19
- 0027375130
- Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
- (1993) Cancer Immunol Immunother , vol.37 , pp. 255-263
- Lewis, G.D.¹ Figari, I.² Fendley, B.³ Wong, W.L.⁴ Carter, P.⁵ Gorman, C.⁶ Shepard, H.M.⁷

20
- 0034767155
- Role of Herceptin® in primary breast cancer: Views from North America and Europe
- (2001) Oncology , vol.61 , Issue.SUPPL. 2 , pp. 83-91
- Leyland-Jones, B.¹ Smith, I.²

21
- 0001228760
- Health related quality of life (HRQL) of patients with HER-2 overexpressing, metastatic breast cancer (MBC) treated with Herceptin (Trastuzumab) as a single agent
- (1999) Proc Am Soc Clin Oncol , vol.18
- Lieberman, G.¹ Burchmore, M.J.² Ferhenbacher, L.³ Cobleigh, M.⁴

22
- 0000153682
- The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
- (2000) Proc Am Soc Clin Oncol , vol.19
- Mass, R.D.¹ Sanders, C.² Charlene, K.³ Everett, T.⁴ Johnson, L.⁵ Anderson, S.⁶

23
- 0024348697
- Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185
- (1989) Oncogene , vol.4 , pp. 543-548
- McKenzie, S.J.¹ Marks, P.J.² Lam, T.³ Morgan, J.⁴ Panicali, D.L.⁵ Trimpe, K.L.⁶ Carney, W.P.⁷

24
- 0033025613
- Third line chemotherapy in patients with metastatic breast cancer: An evaluation of quality of life and cost
- (1999) Breast Cancer Res Treat , vol.54 , pp. 313-323
- McLachlan, S.A.¹ Pintilie, M.² Tannock, I.F.³

25
- 0034761739
- HER2 as a prognostic factor in breast cancer
- (2001) Oncology , vol.61 , Issue.SUPPL. 2 , pp. 67-72
- Ménard, S.¹ Fortis, S.² Castiglioni, F.³ Agresti, R.⁴ Balsari, A.⁵

26
- 0000212829
- Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
- (1999) Proc Am Soc Clin Oncol , vol.18
- Norton, L.¹ Slamon, D.² Leyland-Jones, B.³ Wolter, J.⁴ Fleming, T.⁵ Eirmann, W.⁶ Baselga, J.⁷ Mendelsohn, J.⁸ Bajamonde, A.⁹ Ash, M.¹⁰ Shak, S.¹¹

27
- 0032825105
- Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin)
- (1999) Semin Oncol , vol.26 , Issue.SUPPL. 12 , pp. 84-88
- Osoba, D.¹ Burchmore, M.²

28
- 0031903646
- HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
- (1998) J Clin Oncol , vol.16 , pp. 2659-2671
- Pegram, M.D.¹ Lipton, A.² Hayes, D.F.³ Weber, B.L.⁴ Baselga, J.M.⁵ Tripathy, D.⁶ Baly, D.⁷ Baughman, S.A.⁸ Twaddell, T.⁹ Glaspy, J.A.¹⁰ Slamon, D.J.¹¹

29
- 0029039990
- The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - A review
- (1995) Gene , vol.159 , pp. 19-27
- Ravdin, P.M.¹ Chamness, G.C.²

30
- 0000405942
- Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational controlled phase III trial
- (1998) Proc Am Soc Clin Oncol , vol.17
- Slamon, D.¹ Leyland-Jones, B.² Shak, S.³ Paton, V.⁴ Bajamonde, A.⁵ Fleming, T.⁶ Eirmann, W.⁷ Wolter, J.⁸ Baselga, J.⁹ Norton, L.¹⁰

31
- 37049183697
- Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
- (1987) Science , vol.235 , pp. 177-182
- Slamon, D.J.¹ Clark, G.M.² Wong, S.G.³ Levin, W.J.⁴ Ullrich, A.⁵ McGuire, W.L.⁶

32
- 0024337144
- Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer
- (1989) Science , vol.244 , pp. 707-712
- Slamon, D.J.¹ Godolphin, W.² Jones, L.A.³ Holt, J.A.⁴ Wong, S.G.⁵ Keith, D.E.⁶ Levin, W.J.⁷ Stuart, S.G.⁸ Udove, J.⁹ Ullrich, A.¹⁰ Press, M.F.¹¹

33
- 0035869407
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
- (2001) N Engl J Med , vol.344 , pp. 783-792
- Slamon, D.J.¹ Leyland-Jones, B.² Shak, S.³ Fuchs, H.⁴ Paton, V.⁵ Bajamonde, A.⁶ Fleming, T.⁷ Eiermann, W.⁸ Wolter, J.⁹ Pegram, M.¹⁰ Baselga, J.¹¹ Norton, L.¹²

34
- 0026091927
- Mechanistic aspects of the opposing effects of monoclonal antibodies to the erbB2 receptor on tumor growth
- (1991) Proc Natl Acad Sci USA , vol.88 , pp. 8691-8695
- Stancovski, I.¹ Hurwltz, E.² Leitner, O.³ Ullrich, A.⁴ Yarden, Y.⁵ Sela, M.⁶

35
- 0001793693
- First-line, non-hormonal, treatment of woman with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody)
- (2000) Proc Am Soc Clin Oncol , vol.19
- Vogel, C.¹ Cobleigh, M.² Tripathy, D.³ Harris, L.⁴ Fehrenbacher, L.⁵ Slamon, D.⁶ Ash, M.⁷ Novotny, W.⁸ Stewart, S.⁹ Shak, S.¹⁰

36
- 0034766737
- New combinations with Herceptin® in metastatic breast cancer
- (2001) Oncology , vol.61 , Issue.SUPPL. 2 , pp. 50-57
- Winer, E.P.¹ Burstein, H.J.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.